- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02244229
Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients
September 18, 2014 updated by: Boehringer Ingelheim
MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride.
Study to evaluate the therapeutic effect of tamsulosin and finasteride in symptomatic BPH patients, two medications indicated in BPH belonging to two different pharmacological classes, as evaluated from the point of view of patient's perception of his pathological condition and of the impact of the disease on general health and quality of life
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
403
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years to 78 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Male out-patients aged 50-80 years
- IPSS >= 13 at Visit 1
- Qmax: 4-15 ml/sec at Visit 2
- Residue urinary volume > 400 ml as evaluated by ultrasonography
- SPI >= 7 at Visit 2
- Prostate Specific Antigen (PSA) value < 3 ng/ml at Visit 1, or of 3-10 ng/ml provided that prostate cancer is ruled out on the basis of the usual diagnostic procedures performed at each Centre
- Written informed consent
Exclusion Criteria:
Patients with known history or diagnosis at the time of the screening visit of the following conditions that could influence the end-points of the study:
Urological disturbances
- Medical history of pelvic surgery; palpable bladder at the physical examination, or residue urinary volume > 400 ml; known neurological bladder disorder, bladder neck stenosis, urethral stricture, bladder or prostatic cancer, bladder stone, severe diverticulum of the bladder, symptomatic urinary tract infection during the last month, or recurrent urinary tract infections (more than 2 during the last year); hematuria of unknown origin; diseases that may affect micturition (e.g. diabetes mellitus)
Cardiovascular diseases - The following cardiovascular diseases if occurred in the last 6 months:
- Myocardial infarction
- Unstable angina
- Clinically significant ventricular arrhythmias
- Heart failure (NYHA classes III/IV)
- Orthostatic hypotension
- Cerebral stroke
Neurological diseases
- such as senile dementia, multiple sclerosis, Parkinson's disease, psychiatric disturbances, if their severity could have prevented the correct performance of the trial
Hepatic or renal insufficiency
- (Biochemistry values 15% outside normal laboratory ranges and regarded as clinically relevant by investigator)
- Clinically significant abnormalities in the results of hematologic and biochemical tests performed on blood samples drawn at the screening visit
- Patients who are taking or have been taking α-blockers for BPH or for hypertension or phytotherapy for BPH in the previous 6 weeks
- Patients who are taking or have been taking finasteride in the last 6 months
- Patients who require concomitant drugs which could influence the pharmacodynamic or pharmacokinetic properties of tamsulosin. In particular: alpha-blockers and mixed alpha-beta blockers, alpha- agonists, anti-cholinergics
- Patient who are or have been taking part in a clinical study in the previous 3 months
- Patients who have hypersensitivity or allergic reactions to previously prescribed alpha-blocker(s) or to finasteride
- Patients judged by the investigator to be inappropriate for inclusion in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tamsulosin
|
|
Active Comparator: Finasteride
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in Symptom Problem Index (SPI) by means of validated patient questionnaire
Time Frame: Baseline, after 26 weeks of treatment
|
Baseline, after 26 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Symptom Problem Index (SPI) - by means of validated patient questionnaire
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Change in International Prostatic Symptom Score (IPSS)
Time Frame: up to 52 weeks
|
questionnaire for the self-evaluation of urinary symptoms
|
up to 52 weeks
|
Change in Qmax by means of free flow uroflowmetry
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Number of patients who withdrew due to inefficacy
Time Frame: up to 52 weeks
|
up to 52 weeks
|
|
Number of patients with adverse events
Time Frame: up to 54 weeks
|
up to 54 weeks
|
|
Number of patients with abnormal changes in laboratory parameters
Time Frame: up to 52 weeks
|
up to 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 1998
Primary Completion (Actual)
November 1, 2000
Study Registration Dates
First Submitted
September 18, 2014
First Submitted That Met QC Criteria
September 18, 2014
First Posted (Estimate)
September 19, 2014
Study Record Updates
Last Update Posted (Estimate)
September 19, 2014
Last Update Submitted That Met QC Criteria
September 18, 2014
Last Verified
September 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- 5-alpha Reductase Inhibitors
- Tamsulosin
- Finasteride
Other Study ID Numbers
- 527.15
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States